Suppr超能文献

β细胞替代与再生:1型糖尿病的细胞疗法策略

Beta-cell replacement and regeneration: Strategies of cell-based therapy for type 1 diabetes mellitus.

作者信息

Limbert C, Päth G, Jakob F, Seufert J

机构信息

Division of Endocrinology and Diabetology, Department of Internal Medicine II, University Hospital Freiburg, Freiburg, Germany.

出版信息

Diabetes Res Clin Pract. 2008 Mar;79(3):389-99. doi: 10.1016/j.diabres.2007.06.016. Epub 2007 Sep 12.

Abstract

Pancreatic islet transplantation has demonstrated that long-term insulin independence may be achieved in patients suffering from diabetes mellitus type 1. However, because of limited availability of islet tissue, new sources of insulin producing cells that are responsive to glucose are required. Development of pancreatic beta-cell lines from rodent or human origin has progressed slowly in recent years. Current experiments for ex vivo expansion of beta cells and in vitro differentiation of embryonic and adult stem cells into insulin producing beta-cell phenotypes led to promising results. Nevertheless, the cells generated to date lack important characteristics of mature beta cells and generally display reduced insulin secretion and loss of proliferative capacity. Therefore, much better understanding of the mechanisms that regulate expansion and differentiation of stem/progenitor cells is necessary. Here, we review recent advances in the identification of potential cellular sources, and the development of strategies to regenerate or fabricate insulin producing and glucose sensing cells that might enable future cell-based therapies of diabetes mellitus type 1.

摘要

胰岛移植已证明,1型糖尿病患者有可能实现长期胰岛素非依赖。然而,由于胰岛组织供应有限,需要有对葡萄糖有反应的新的胰岛素产生细胞来源。近年来,源自啮齿动物或人类的胰腺β细胞系的开发进展缓慢。目前关于β细胞体外扩增以及胚胎干细胞和成人干细胞体外分化为产生胰岛素的β细胞表型的实验已取得了令人鼓舞的结果。尽管如此,迄今为止所产生的细胞缺乏成熟β细胞的重要特征,通常表现出胰岛素分泌减少和增殖能力丧失。因此,有必要更好地了解调节干细胞/祖细胞扩增和分化的机制。在此,我们综述了在确定潜在细胞来源以及开发再生或制造产生胰岛素和感知葡萄糖的细胞的策略方面的最新进展,这些进展可能使未来基于细胞的1型糖尿病治疗成为可能。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验